| Literature DB >> 20354024 |
Behzad Nadjm1, Ben Amos, George Mtove, Jan Ostermann, Semkini Chonya, Hannah Wangai, Juma Kimera, Walii Msuya, Frank Mtei, Denise Dekker, Rajabu Malahiyo, Raimos Olomi, John A Crump, Christopher J M Whitty, Hugh Reyburn.
Abstract
OBJECTIVES: To assess the performance of WHO's "Guidelines for care at the first-referral level in developing countries" in an area of intense malaria transmission and identify bacterial infections in children with and without malaria.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20354024 PMCID: PMC2847687 DOI: 10.1136/bmj.c1350
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
WHO criteria for presumptive antimicrobial treatment in children admitted to hospital
| WHO criteria | Recommended antimicrobial | Chapter, page of guidelines for care at first referral level8 |
|---|---|---|
| Sick young infant—any infant aged <2 months admitted to hospital (not included in this study) | Ampicillin plus gentamicin IV/IM or penicillin plus gentamicin IV/IM | 6.1, 75 |
| Meningo-encephalopathy—BCS<3 or stiff neck or bulging fontanelle or >2 convulsions in preceding 24 hours | Chloramphenicol plus ampicillin IV/IM or chloramphenicol plus penicillin IV/IM | 5.2, 62 |
| Malaria with shock*—positive slide for malaria plus shock† or BCS<3 or bulging fontanelle or >2 convulsions in preceding 24 hours | Chloramphenicol plus penicillin IV/IM | 5.1.1, 59† |
| Very severe pneumonia—cough/difficulty breathing plus multiple convulsions or coma or lethargy or vomiting everything or inability to drink or cyanosis or severe respiratory distress‡ | Chloramphenicol IV/IM or gentamicin plus penicillin IV/IM§ | 3.1.1, 30 |
| Severe pneumonia—cough/difficulty breathing plus lower chest indrawing or nasal flaring or grunting | Benzyl penicillin IV/IM | 3.1.2, 32 |
| Non-severe pneumonia—cough/difficulty breathing plus raised respiratory rate for age | Amoxycillin PO or co-trimoxazole PO | 3.1.3, 32 |
| Septicaemia—negative slide for malaria plus axillary temperature ≥37.5°C plus inability to drink/feed or lethargy or >2 convulsions in preceding 24 hours or vomiting everything | Chloramphenicol plus penicillin IV/IM | 5.4, 67 |
| Severe acute malnutrition—bilateral oedema or severe wasting or weight for height z-score <−3 | Co-trimoxazole PO or amoxycillin plus gentamicin¶ IM/IV | 7.2.5, 84 |
Where categories were used in analysis, children were assigned to one diagnostic category with priority to those higher in list.
BCS=Blantyre coma score; IM=intramuscular; IV=intravenous; PO=oral.
*“Malaria with shock or signs of meningitis” defined in WHO guidelines8; however, children with malaria and signs of meningitis will already be included in category above.
†Shock defined as capillary refill >3 seconds or cool peripheries or systolic blood pressure <50 mm Hg (WHO Pocket Book of Hospital Care for Children 6.2.1, 142).
‡Defined as oxygen saturation <90% or respiratory rate ≥70 breaths/minute.
§Recommended if chloramphenicol is not available.
¶Recommended if hypoglycaemia or hypothermia present or if child seems lethargic or “sickly.”

Fig 1 Admissions, deaths, inclusions, and exclusions during study. 2383/3639 (65.5%) had an axillary temperature ≥37.5 on admission, 1234/3639 (33.9%) were afebrile with a history of fever, and 22/3639 (0.6%) gave a history of fever with no temperature recorded

Fig 2 Numbers and deaths of children infected with P falciparum by blood slide, invasive bacterial disease (IBD), or HIV. Areas in Venn diagram approximately to scale. *IBD consisted of 336 children with a positive blood culture, of whom 20 also had a positive cerebrospinal fluid (CSF) culture, and an additional five with a pathogenic organism isolated from CSF and a negative or contaminated blood culture. †Blood cultures classified as negative included 251 (6.9%) from which contaminant organisms only were cultured. ‡Three negative HIV results were based on Capillus testing only (negative predictive value 99.5%, detail not shown); all other HIV results were based on at least two concordant test results
Sensitivity and specificity of WHO “guidelines for care at first-referral level” criteria for antimicrobial treatment in identifying children with invasive bacterial disease (IBD) by rapid diagnostic test (RDT) and blood slide results
| Total cases (No; % died) | No (%) with IBD | Sensitivity—% (95% CI) | Specificity—% (95% CI) | PPV (%) | NPV (%) | NNT* | % fatal cases with IBD treated† | |
|---|---|---|---|---|---|---|---|---|
| RDT and slide negative‡ | 943 (56; 5.9) | 143 (15.2) | 72.7 (69.9 to 75.6) | 47.3 (44.1 to 50.4) | 19.8 | 90.6 | 5.1 | 88.9 |
| RDT positive, slide negative§ | 501 (33; 6.6) | 98 (19.6) | 67.3 (63.2 to 71.5) | 49.9 (45.5 to 54.3) | 24.6 | 86.3 | 4.1 | 83.3 |
| Slide positive <5000/μl | 405 (19; 4.7) | 33 (8.1) | 60.6 (55.9 to 65.4) | 51.9 (47.0 to 56.8) | 10.1 | 93.7 | 10.1 | 80.0 |
| Slide positive 5000-50 000/μl | 917 (33; 3.6) | 31 (3.4) | 67.7 (64.7 to 70.8) | 55.9 (52.7 to 59.1) | 5.1 | 98.0 | 19.6 | 66.7 |
| Slide positive >50 000/μl | 873 (43; 4.9) | 36 (4.1) | 52.8 (49.5 to 56.1) | 51.6 (48.3 to 54.9) | 4.5 | 96.2 | 22.3 | 60.0 |
NPV=negative predictive value; PPV=positive predictive value.
*Number needed to treat presumptively with antimicrobials to correctly treat one child with IBD.
†Proportion of all IBD associated fatalities with “guidelines for care at first-referral level” indication for antimicrobial treatment.
‡56 children were RDT negative and blood slide positive and are included in slide positive data (sensitivity of RDT compared with slide reading was 97.4%).
§Assumed to indicate recent infection with P falciparum.
Number (%) of children with and without one of WHO indications for antimicrobial treatment by organism isolated from blood or cerebrospinal fluid
| Guidelines indication | Non-typhi | Other Gram negative* | Strep pneumoniae | Other Gram positive† | No organism isolated | Total | |
|---|---|---|---|---|---|---|---|
| Meningo-encephalopathy | 7 (3) | 18 (7) | 5 (2) | 5 (2) | 4 (2) | 216 (85) | 255 |
| Malaria with shock | 4 (5) | 0 | 2 (2) | 0 | 0 | 76 (93) | 82 |
| Very severe pneumonia | 31 (8) | 6 (2) | 10 (3) | 15 (4) | 5 (3) | 311 (82) | 378 |
| Severe pneumonia | 13 (7) | 5 (3) | 2 (1) | 9 (5) | 1 (5) | 171 (85) | 201 |
| Non-severe pneumonia | 39 (5) | 4 (1) | 15 (2) | 15 (2) | 6 (1) | 766 (91) | 845 |
| Septicaemia | 1 (4) | 0 | 1 (4) | 1 (4) | 0 | 25 (89) | 28 |
| Severe acute malnutrition | 2 (5) | 1 (3) | 2 (5) | 1 (3) | 0 | 34 (85) | 40 |
| No WHO indication‡ | 63 (3.5) | 5 (0.3) | 24 (1.3) | 10 (0.6) | 9 (0.5) | 1699 (93.9) | 1810 |
One child in whom Strep pneumoniae was isolated from cerebrospinal fluid and non-typhi Salmonella was isolated from blood was classified as infected with Strep pneumoniae alone.
*Included 23 E coli and 11 Salmonella typhi.
†Included 17 Staph aureus.
‡225/1810 (12.4%) of children who did not meet an existing WHO indication for antimicrobial treatment had severe anaemia (haemoglobin <5 g/dl).

Fig 3 Proportion of organisms isolated from children with invasive bacterial disease by P falciparum infection status. RDT=rapid diagnostic test
Logistic regression model of factors associated with invasive bacterial disease in all children in study
| Factors | Unadjusted odds ratio (95% CI) | Adjusted odds ratio (95% CI) |
|---|---|---|
| WHO criteria | 2.20 (1.74 to 2.79)** | 1.67 (1.28 to 2.17)** |
| Meningo-encephalopathy | 1.84 (1.28 to 2.64)** | |
| Malaria with shock | 0.59 (0.34 to 1.00) | |
| Very severe pneumonia | 2.16 (1.67 to 2.81)** | |
| Severe pneumonia | 1.85 (1.25 to 2.74)** | |
| Non-severe pneumonia | 0.98 (0.75 to 1.28) | |
| Septicaemia | 5.58 (3.92 to 7.96)** | |
| Severe acute malnutrition | 1.72 (0.72 to 4.13) | |
| HIV positive | 2.38 (1.54 to 3.68)** | 1.47 (0.91 to 2.35) |
| Axillary temperature >38°C | 1.34 (1.07 to 1.67)* | 1.44 (1.13 to 1.84)** |
| Prostration† | 1.42 (1.03 to 1.95)* | 1.01 (0.65 to 1.55) |
| Shock | 1.14 (0.69 to 1.88) | 0.90 (0.50 to 1.60) |
| Haemoglobin <5 g/dl | 1.43 (1.08 to 1.89)* | 1.56 (1.13 to 2.14)** |
| Glucose <2.5 mmol/l | 2.33 (1.44 to 3.75)** | 2.46 (1.39 to 4.35)** |
| Lactate >5 mmol/l | 1.46 (1.07 to 1.99)* | |
| Slide positive | 0.24 (0.19 to 0.30)** | |
| RDT positive, slide negative‡ | 2.90 (2.24 to 3.75)** | 1.29 (0.95 to 1.75) |
| Slide positive <5000/μl | 0.84 (0.58 to 1.23) | 0.55 (0.36 to 0.84)** |
| Slide positive 5000-50 000/μl | 0.27 (0.19 to 0.40)** | 0.20 (0.13 to 0.31)** |
| Slide positive >50 000/μl | 0.35 (0.24 to 0.50)** | 0.24 (0.16 to 0.37)** |
RDT=rapid diagnostic test.
*P<0.05.
**P<0.001.
†Inability to sit unsupported or, if age <8 months, inability to drink.
‡RDT positive and slide negative assumed to indicate recent infection with P falciparum.
Sensitivity, specificity, and predictive values of selected additions to WHO “guidelines for care at first-referral level” criteria for presumptive treatment of invasive bacterial disease (IBD) by presence or absence of P falciparum parasitaemia
| Sensitivity—% (95% CI) | Specificity—% (95% CI) | PPV (%) | NPV (%) | NNT* | % fatal cases with IBD treated† | |
|---|---|---|---|---|---|---|
| A—guidelines criteria | 60.0 (58.0 to 62.1) | 53.5 (51.4 to 55.6) | 5.8 | 96.6 | 17.3 | 69.2 |
| B—A or HIV | 62.0 (60.0 to 64.0) | 52.5 (50.4 to 54.6) | 5.9 | 96.7 | 17.1 | 69.2 |
| C—B or severe anaemia | 68.0 (66.1 to 70.0) | 45.3 (43.2 to 47.4) | 5.6 | 96.7 | 17.9 | 84.6 |
| D—C or prostration | 72.0 (70.1 to 73.9) | 43.4 (41.4 to 45.5) | 5.7 | 97.0 | 17.5 | 92.3 |
| E—D or axillary temperature >38°C | 86.0 (84.6 to 87.5) | 22.3 (20.6 to 24.0) | 5.0 | 97.1 | 19.9 | 92.3 |
| A—guidelines criteria | 70.5 (68.2 to 72.9) | 48.1 (45.6 to 50.7) | 21.4 | 89.1 | 4.7 | 86.7 |
| B—A or HIV | 71.4 (69.0 to 73.7) | 46.6 (44.1 to 49.2) | 21.1 | 89.0 | 4.7 | 86.7 |
| C—B or severe anaemia | 75.5 (73.3 to 77.7) | 42.4 (39.9 to 44.9) | 20.8 | 89.6 | 4.8 | 88.9 |
| D—C or prostration | 75.9 (73.7 to 78.1) | 42.0 (39.4 to 44.5) | 20.8 | 89.7 | 4.8 | 91.1 |
| E—D or axillary temperature >38°C | 86.3 (84.5 to 88.1) | 29.3 (26.9 to 31.6) | 19.6 | 91.4 | 5.1 | 93.3 |
NPV=negative predictive value; PPV=positive predictive value.
*Number needed to treat presumptively with antimicrobials to correctly treat one child with IBD.
†Proportion of all IBD associated fatalities identified for antimicrobial treatment.
Proportion (%) of bacterial isolates susceptible in vitro to recommended and other commonly available antimicrobials by WHO “guidelines for care at first-referral level” criteria for antimicrobial treatment*
| Amp/chlor | Pen/chlor | Chlor | Pen/gent† | Pen | Amoxy | Co-trimox | Amp/ gent† | Ceftriaxone | Pen/ cipro | Azithromycin | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Meningo-encephalopathy | 22/34 (65)‡ | 19/34 (56) | 16/32 (50) | 22/24 (92) | 5/38 (13) | 13/34 (38) | 6/25 (24) | 28/29 (97) | 31/31 (100) | 12/13 (92) | 26/29 (90) |
| Malaria with shock | 2/6 (33) | 2/6 (33)‡ | 2/6 (33) | 4/5 (80) | 0/6 (0) | 2/6 (33) | 3/5 (60) | 4/5 (80) | 5/6 (83) | 5/5 (100) | 3/8 (38) |
| Very severe pneumonia | 32/62 (52) | 31/63(49) | 26/62 (42)‡ | 54/60 (90) | 16/65 (25) | 26/62 (42) | 17/58 (29) | 55/60 (92) | 60/61 (98) | 53/53 (100) | 38/55 (69) |
| Severe pneumonia | 20/29 (69) | 19/30 (63) | 17/29 (59) | 29/29 (100) | 10/30 (33)‡ | 18/29 (62) | 9/26 (35) | 29/29 (100) | 30/30 (100) | 23/23 (100) | 27/35 (77) |
| Non-severe pneumonia | 38/69 (55) | 36/69 (52) | 30/66 (46) | 63/72 (88) | 16/76 (21) | 32/71 (45)‡ | 21/66 (32) | 63/72 (88) | 71/72 (996) | 67/67 (100) | 57/86 (66) |
| Septicaemia | 1/2 (50) | 1/2 (50)‡ | 1/2 (50) | 3/3 (100) | 1/3 (33) | 1/2 (50) | 1/2 (50) | 3/3 (100) | 2/2 (100) | 3/3 (100) | 4/5 (75) |
| Severe acute malnutrition | 5/6 (83) | 5/6 (83) | 5/6 (83) | 5/5 (100) | 1/6 (17) | 4/6 (67) | 3/5 (60) | 6/6 (100)‡ | 6/6 (100) | 5/5 (100) | 3/5 (60) |
Amoxy=amoxicillin; amp=ampicillin; chlor=chloramphenicol; co-trimox=co-trimoxazole; cipro=ciprofloxacin; gent=gentamicin; pen=penicillin.
*Susceptibility includes “full” or “intermediate” susceptibility and follows Clinical Laboratory Standards Institute (CLSI) guidelines with exception of susceptibility of Salmonella isolates (noted below)20; not all isolates were tested for all antibiotics.
†Salmonella susceptibilities to gentamicin are shown as actual in vitro results, although CLSI guidelines recommend that for clinical practice all Salmonella should be reported as “not susceptible” owing to poor intracellular penetration of gentamicin.
‡First recommendation treatment.
Proportion (%) of bacterial isolates susceptible in vitro to commonly available antimicrobials
| Penicillin/amoxicillin | Chloramphenicol | Co-trimoxazole | Gentamicin | |
|---|---|---|---|---|
| Non-typhi | 49/148 (33) | 53/153 (35) | 49/145 (34) | 147/152 (97)† |
| Strep pneumoniae | 51/51 (100) | 41/48 (85) | 22/45 (49) | – |
| Haemophilus influenzae | 12/38 (32) | 16/38 (42) | 2/28 (7) | 22/23 (96) |
| E coli | 2/21 (10) | 5/18 (28) | 1/20 (5) | 9/20 (45) |
| Staph aureus | 1/15 (7) | 11/13 (85) | 10/14 (71) | 13/16 (81) |
Susceptibility includes “full” or “intermediate” susceptibility and follows Clinical Laboratory Standards Institute (CLSI) guidelines with exception of susceptibility of Salmonella isolates (noted below).20
*Salmonella isolates were multi-resistant (resistant to amoxicillin, chloramphenicol, and co-trimoxazole) in 85/141 (60.3%) cases.
†Salmonella susceptibilities to gentamicin are shown as actual in vitro results, although CLSI guidelines recommend that for clinical practice all Salmonella should be reported as “not susceptible” owing to poor intracellular penetration of gentamicin.